Entity

Time filter

Source Type

BALTIMORE, MD, United States

The current invention involves biologically active proteins termed stradobodies. The stradobodies have two or more domains that create stradobody multimers. The stradobodies have both antigen-binding capacity and the ability to bind Fc receptors (FcR), and are useful in the treatment and prevention of disease.


Patent
Gliknik Inc. | Date: 2010-05-13

The current invention provides a method of treating a mammal in need of such treatment with aggregated IgG derived from pooled human plasma. The invention further provides using the discarded fraction obtained during the course of standard IgG fractionation as the source of the aggregated IgG. The methods of the invention further provide for enhancing the aggregation of the aggregate fraction as well as enriching and modifying glycoforms.


Patent
Gliknik Inc. and University of Maryland, Baltimore | Date: 2014-03-20

IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compounds efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.


Patent
Gliknik Inc. | Date: 2013-01-28

The present invention relates to biologically active fusion proteins containing the IgG2 hinge as a multimerization domain capable of multimerizing proteins, peptides and small molecules which are active or more active in multimeric form; compositions comprising such fusion proteins; and methods of making and using such fusion proteins.


Patent
Gliknik Inc. and University of Maryland, Baltimore | Date: 2013-12-17

IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compounds efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.

Discover hidden collaborations